Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

The effects of population-based mammography screening starting between age 40 and 50 in the presence of adjuvant systemic therapy.

de Gelder R, Heijnsdijk EA, Fracheboud J, Draisma G, de Koning HJ.

Int J Cancer. 2015 Jul 1;137(1):165-72. doi: 10.1002/ijc.29364. Epub 2014 Dec 13.

2.

Treatment of local-regional prostate cancer detected by PSA screening: benefits and harms according to prognostic factors.

Wever EM, Heijnsdijk EA, Draisma G, Bangma CH, Roobol MJ, Schröder FH, de Koning HJ.

Br J Cancer. 2013 May 28;108(10):1971-7. doi: 10.1038/bjc.2013.198. Epub 2013 May 14.

3.

A note on the catch-up time method for estimating lead or sojourn time in prostate cancer screening.

Draisma G, van Rosmalen J.

Stat Med. 2013 Aug 30;32(19):3332-41. doi: 10.1002/sim.5750. Epub 2013 Jan 31.

4.

Quality-of-life effects of prostate-specific antigen screening.

Heijnsdijk EA, Wever EM, Auvinen A, Hugosson J, Ciatto S, Nelen V, Kwiatkowski M, Villers A, Páez A, Moss SM, Zappa M, Tammela TL, Mäkinen T, Carlsson S, Korfage IJ, Essink-Bot ML, Otto SJ, Draisma G, Bangma CH, Roobol MJ, Schröder FH, de Koning HJ.

N Engl J Med. 2012 Aug 16;367(7):595-605. doi: 10.1056/NEJMoa1201637.

5.

To be screened or not to be screened? Modeling the consequences of PSA screening for the individual.

Wever EM, Hugosson J, Heijnsdijk EA, Bangma CH, Draisma G, de Koning HJ.

Br J Cancer. 2012 Aug 21;107(5):778-84. doi: 10.1038/bjc.2012.317. Epub 2012 Jul 17.

6.

Differences in natural history between breast cancers in BRCA1 and BRCA2 mutation carriers and effects of MRI screening-MRISC, MARIBS, and Canadian studies combined.

Heijnsdijk EA, Warner E, Gilbert FJ, Tilanus-Linthorst MM, Evans G, Causer PA, Eeles RA, Kaas R, Draisma G, Ramsay EA, Warren RM, Hill KA, Hoogerbrugge N, Wasser MN, Bergers E, Oosterwijk JC, Hooning MJ, Rutgers EJ, Klijn JG, Plewes DB, Leach MO, de Koning HJ.

Cancer Epidemiol Biomarkers Prev. 2012 Sep;21(9):1458-68. doi: 10.1158/1055-9965.EPI-11-1196. Epub 2012 Jun 28.

7.

The prostate cancer conundrum revisited: treatment changes and prostate cancer mortality declines.

Etzioni R, Gulati R, Tsodikov A, Wever EM, Penson DF, Heijnsdijk EA, Katcher J, Draisma G, Feuer EJ, de Koning HJ, Mariotto AB.

Cancer. 2012 Dec 1;118(23):5955-63. doi: 10.1002/cncr.27594. Epub 2012 May 17.

8.

Prediction of higher mortality reduction for the UK Breast Screening Frequency Trial: a model-based approach on screening intervals.

van Ravesteyn NT, Heijnsdijk EA, Draisma G, de Koning HJ.

Br J Cancer. 2011 Sep 27;105(7):1082-8. doi: 10.1038/bjc.2011.300. Epub 2011 Aug 23.

9.

Digital mammography screening: weighing reduced mortality against increased overdiagnosis.

de Gelder R, Fracheboud J, Heijnsdijk EA, den Heeten G, Verbeek AL, Broeders MJ, Draisma G, de Koning HJ.

Prev Med. 2011 Sep;53(3):134-40. doi: 10.1016/j.ypmed.2011.06.009. Epub 2011 Jun 21.

PMID:
21718717
10.

Interpreting overdiagnosis estimates in population-based mammography screening.

de Gelder R, Heijnsdijk EA, van Ravesteyn NT, Fracheboud J, Draisma G, de Koning HJ.

Epidemiol Rev. 2011;33:111-21. doi: 10.1093/epirev/mxr009. Epub 2011 Jun 27. Review.

11.

What if I don't treat my PSA-detected prostate cancer? Answers from three natural history models.

Gulati R, Wever EM, Tsodikov A, Penson DF, Inoue LY, Katcher J, Lee SY, Heijnsdijk EA, Draisma G, de Koning HJ, Etzioni R.

Cancer Epidemiol Biomarkers Prev. 2011 May;20(5):740-50. doi: 10.1158/1055-9965.EPI-10-0718.

12.

How does early detection by screening affect disease progression? Modeling estimated benefits in prostate cancer screening.

Wever EM, Draisma G, Heijnsdijk EA, de Koning HJ.

Med Decis Making. 2011 Jul-Aug;31(4):550-8. doi: 10.1177/0272989X10396717. Epub 2011 Mar 15.

13.

Population-based mammography screening below age 50: balancing radiation-induced vs prevented breast cancer deaths.

de Gelder R, Draisma G, Heijnsdijk EA, de Koning HJ.

Br J Cancer. 2011 Mar 29;104(7):1214-20. doi: 10.1038/bjc.2011.67. Epub 2011 Mar 1.

14.

Health Service Interventions for Cancer Control in Developing Countries.

Brown ML, Goldie SJ, Draisma G, Harford J, Lipscomb J.

In: Jamison DT, Breman JG, Measham AR, Alleyne G, Claeson M, Evans DB, Jha P, Mills A, Musgrove P, editors. Disease Control Priorities in Developing Countries. 2nd edition. Washington (DC): World Bank; 2006. Chapter 29.

15.

Race-specific impact of natural history, mammography screening, and adjuvant treatment on breast cancer mortality rates in the United States.

van Ravesteyn NT, Schechter CB, Near AM, Heijnsdijk EA, Stoto MA, Draisma G, de Koning HJ, Mandelblatt JS.

Cancer Epidemiol Biomarkers Prev. 2011 Jan;20(1):112-22. doi: 10.1158/1055-9965.EPI-10-0944. Epub 2010 Nov 30.

16.

Prostate-specific antigen screening in the United States vs in the European Randomized Study of Screening for Prostate Cancer-Rotterdam.

Wever EM, Draisma G, Heijnsdijk EA, Roobol MJ, Boer R, Otto SJ, de Koning HJ.

J Natl Cancer Inst. 2010 Mar 3;102(5):352-5. doi: 10.1093/jnci/djp533. Epub 2010 Feb 8.

17.

Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms.

Mandelblatt JS, Cronin KA, Bailey S, Berry DA, de Koning HJ, Draisma G, Huang H, Lee SJ, Munsell M, Plevritis SK, Ravdin P, Schechter CB, Sigal B, Stoto MA, Stout NK, van Ravesteyn NT, Venier J, Zelen M, Feuer EJ; Breast Cancer Working Group of the Cancer Intervention and Surveillance Modeling Network.

Ann Intern Med. 2009 Nov 17;151(10):738-47. doi: 10.7326/0003-4819-151-10-200911170-00010. Erratum in: Ann Intern Med. 2010 Jan 19;152(2):136.

18.

Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer.

Heijnsdijk EA, der Kinderen A, Wever EM, Draisma G, Roobol MJ, de Koning HJ.

Br J Cancer. 2009 Dec 1;101(11):1833-8. doi: 10.1038/sj.bjc.6605422. Epub 2009 Nov 10.

19.

Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context.

Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E, Gulati R, Feuer E, de Koning H.

J Natl Cancer Inst. 2009 Mar 18;101(6):374-83. doi: 10.1093/jnci/djp001. Epub 2009 Mar 10.

20.

Cost-effectiveness of opportunistic versus organised mammography screening in Switzerland.

de Gelder R, Bulliard JL, de Wolf C, Fracheboud J, Draisma G, Schopper D, de Koning HJ.

Eur J Cancer. 2009 Jan;45(1):127-38. doi: 10.1016/j.ejca.2008.09.015. Epub 2008 Nov 27.

PMID:
19038540
21.

Breast cancer screening policies in developing countries: a cost-effectiveness analysis for India.

Okonkwo QL, Draisma G, der Kinderen A, Brown ML, de Koning HJ.

J Natl Cancer Inst. 2008 Sep 17;100(18):1290-300. doi: 10.1093/jnci/djn292. Epub 2008 Sep 9.

PMID:
18780864
22.

Breast cancer screening: evidence for false reassurance?

de Gelder R, van As E, Tilanus-Linthorst MM, Bartels CC, Boer R, Draisma G, de Koning HJ.

Int J Cancer. 2008 Aug 1;123(3):680-6. doi: 10.1002/ijc.23540.

23.

Risk-based selection from the general population in a screening trial: selection criteria, recruitment and power for the Dutch-Belgian randomised lung cancer multi-slice CT screening trial (NELSON).

van Iersel CA, de Koning HJ, Draisma G, Mali WP, Scholten ET, Nackaerts K, Prokop M, Habbema JD, Oudkerk M, van Klaveren RJ.

Int J Cancer. 2007 Feb 15;120(4):868-74.

24.

Cost-effectiveness of different reading and referral strategies in mammography screening in the Netherlands.

Groenewoud JH, Otten JD, Fracheboud J, Draisma G, van Ineveld BM, Holland R, Verbeek AL, de Koning HJ; NETB.

Breast Cancer Res Treat. 2007 Apr;102(2):211-8. Epub 2006 Sep 27.

PMID:
17004116
25.

Gleason score, age and screening: modeling dedifferentiation in prostate cancer.

Draisma G, Postma R, Schröder FH, van der Kwast TH, de Koning HJ.

Int J Cancer. 2006 Nov 15;119(10):2366-71.

26.

Overdiagnosis and overtreatment of breast cancer: microsimulation modelling estimates based on observed screen and clinical data.

de Koning HJ, Draisma G, Fracheboud J, de Bruijn A.

Breast Cancer Res. 2006;8(1):202. Epub 2005 Dec 21.

27.

Seventy-five years is an appropriate upper age limit for population-based mammography screening.

Fracheboud J, Groenewoud JH, Boer R, Draisma G, de Bruijn AE, Verbeek AL, de Koning HJ.

Int J Cancer. 2006 Apr 15;118(8):2020-5.

28.

Trends in the usage of adjuvant systemic therapy for breast cancer in the Netherlands and its effect on mortality.

Vervoort MM, Draisma G, Fracheboud J, van de Poll-Franse LV, de Koning HJ.

Br J Cancer. 2004 Jul 19;91(2):242-7.

29.

Mammography benefit in the Canadian National Breast Screening Study-2: a model evaluation.

Rijnsburger AJ, van Oortmarssen GJ, Boer R, Draisma G, To T, Miller AB, de Koning HJ.

Int J Cancer. 2004 Jul 10;110(5):756-62.

30.

MISCAN: estimating lead-time and over-detection by simulation.

Draisma G, De Koning HJ.

BJU Int. 2003 Dec;92 Suppl 2:106-11.

31.

Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer.

Draisma G, Boer R, Otto SJ, van der Cruijsen IW, Damhuis RA, Schröder FH, de Koning HJ.

J Natl Cancer Inst. 2003 Jun 18;95(12):868-78.

PMID:
12813170
32.

Supplemental Content

Loading ...
Support Center